N/A N=197 Pancreaticobiliary Reflux in Patients Without Cholelithiasis
Pancreaticobiliary Reflux
Primary: Amylase and Lipase Values in Gallbladder Bile — 5.5; 181.2; 9.5; 434.8 mg/dl
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=250 Non-Complex Biliary Stones DSC vs ERC
Biliary Stones
Primary: Number of Participants With Complete Stone Clearance — 112; 108 Participants — p=0.029
N/A N=75 The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Management of Pancreaticobiliary Disorders
Disorders of the Pancreas and Biliary Tree
Primary: Successful Procedure Completion — 70; 5 participants
N/A N=100 The Use of Fluorescent Imaging for Intraoperative Cholangiogram During Laparoscopic Cholecystectomy
Cholelithiasis · Cholecystitis · Pancreatitis Biliary
Primary: Operative Time — 51.6; 44.4 minutes
Phase 4 N=23 Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy
Bile Acid Malabsorption · Cholelithiasis
Primary: Change in Stimulated Fibroblast Growth Factor 19 (FGF19) From Baseline Before Versus Post Cholecystectomy — 81; 186 pg per mL — p=0.03
N/A N=677 Fluorescent Cholangiography vs White Light for Bile Ducts Identification
Cholecystitis · Cholelithiasis
Primary: Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light — 64; 157; 159; 243 Participants
N/A N=99 Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy
Cholecystitis
Primary: Complications Related to ICG — 0; 0 % of Participants with Complications
Phase 4 N=138 Effect of Rowachol on Prevention of Postcholecystectomy Syndrome
Postcholecystectomy Syndrome
Primary: the Number of the Participants Have Postoperative RUQ Pain — 3; 9 number of participants
N/A N=88 Clinical Utility of ERCP Guided Cholangiopancreatoscopy With the SpyGlass DS
Biliary Tract Disease
Primary: Number of Participants With Procedure Technical Success — 70; 3 participants
N/A N=19 FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis
Cholecystitis
Primary: Sensitivity and Specificity of FDG PET/CT and Tc99mHIDA in the Evaluation of Subjects Suspected of Cholecystitis — 9; 0; 1; 1 Participants
N/A N=7 Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy
Pancreatobiliary Disease · Altered Gastric Anatomy
Primary: Papilla or Duct-enterostomy Was Reached — 10 ERCPs
N/A N=7 Optical Frequency Domain Imaging (OFDI) for Biliary Stricture Imaging
Biliary Stricture
Primary: Feasibility of Imaging the Bile Duct With the OFDI Probe — 7 Participants
Phase 4 N=108 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma
Hilar Cholangiocarcinoma
Primary: Proportion of Patients With Adequate Biliary Drainage in Metallic Stent and Plastic Stent Group.(ITT Analysis) — .7037037; .46296 proportion of participants — p=0.011
N/A N=106 Drain After Elective Laparoscopic Cholecystectomy
Cholelithiasis
Primary: Number of Participants With Subhepatic Collection at Ultrasonographic Examination — 45; 46 Participants
N/A N=198 Effects of Drainage in Laparoscopic Cholecystectomy
Acute Cholecystitis · Empyema of Gallbladder · Abscess of Gallbladder
Primary: Complication — 7; 7 participants
N/A N=137 Gentamicin in Preventing Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Cholangitis in Non-calculus Stenting
Cholangitis
Primary: Number of Participants With Cholangitis — 5; 5 participants — p=<0.05
Phase 4 N=200 Clinical Trial for the Optimization of Indocyanine Green Administration in NIRF-C During L.Cholecystectomy.
Laparoscopic Cholecystectomy
Primary: Identification of Biliary Structures Prior to Dissection of the Hepatocystic Triangle. — 26; 20; 26; 29 Participants
Phase 2 N=44 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
Cancer of the Gallbladder · Cancer of the Biliary Tract
Primary: Number of Participants With Objective Response — 1 participants
N/A N=30 AXIOS™ for Gallbladder Drainage as an Alternative to Percutaneous Drainage IDE
Cholecystitis, Acute
Primary: Number of Days to Resolution of Acute Cholecystitis — 5.30 days
N/A N=327 Prospective Evaluation of Biliary Tissue Sampling With ERCP
Cholangiopancreatography, Endoscopic Retrograde · Biliary Stricture · Biliary Tract Diseases
Primary: Performance Characteristics — 84.09; 56.98; 94.87 Percentage
N/A N=63 Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction
Pancreatic Cancer
Primary: Assess the Occlusion Rates, Attempted Surgical Resection or Death of Plastic, Covered, and Uncovered Biliary Stents in Patients Presenting With Malignant Biliary…
N/A N=7 A Trial to Evaluate Natural Orifice Transvaginal Endoscopic Cholecystectomy With Laparoscopic Assistance
Gallbladder Disease
Primary: Procedure Completion — 7 participants
N/A N=253 Laparoscopic Versus Transabdominal Ultrasound in Morbidly Obese Patients
Cholelithiasis · Ultrasonography · Laparoscopic Gastric Bypass
Primary: Cholelithiasis on Transabdominal Ultrasound Versus Laparoscopic Ultrasound. — 61; 60 participants — p=0.763
Phase 1 N=22 Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT
Cholestasis · Primary Sclerosing Cholangitis · Primary Biliary Cirrhosis
Primary: Percentage of Participants in Whom we Could Quantify Hepatic Transport of 11C-CSar — 100; 100 percentage of participants
N/A N=129 A Trial Comparing the Uncovered to the Covered Wallstent in the Palliation of Malignant Bile Duct Strictures
Inoperable Tumors of the Bile Duct
Primary: Time to Recurrent Biliary Obstruction — 711; 357 days — p=0.530
Phase 2 N=105 S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Phase 4 N=50 Evaluation of Gallbladder Contractility Using Both CCK and Milk Consecutively
Abdominal Pain
Primary: Gallbladder Ejection Fraction — 15 percentage of ejection of tracer
Phase 3 N=74 A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction
Cholestasis, Extrahepatic
Primary: Adequate Clinical Palliation of the Biliary Obstruction — 54 participants
Phase 3 N=187 WallFlex Biliary Fully Covered (FC) Benign Stricture Study
Biliary Stricture
Primary: Stent Removability — 132 Participants
Phase 2 N=23 Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
Type 2 Diabetes Mellitus · Obese · Overweight
Primary: Change in Postprandial Glucose — -2803; 629 mmol/6hr — p=<0.05